The use of Monte Carlo simulation to predict vancomycin dosage for methicillin-resistant Staphylococcus aureus in Thai patients of various ages and with varying degrees of renal function
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.
Yamamoto M, Kuzuya T, Baba H, Yamada K, Nabeshima T. Population pharmacokinetic analysis of vancomycin in patients with gram-positive infections and the influence of infectious disease type. J Clin Pharm Ther. 2009; 34:473–83.10.1111/j.1365-2710.2008.01016.x19583681YamamotoMKuzuyaTBabaHYamadaKNabeshimaT.Population pharmacokinetic analysis of vancomycin in patients with gram-positive infections and the influence of infectious disease type20093447383Open DOISearch in Google Scholar
Sánchez JL, Dominguez AR, Lane JR, Anderson PO, Capparelli EV, Cornejo-Bravo JM. Population pharmacokinetics of vancomycin in adult and geriatric patients: comparison of eleven approaches. Int J Clin Pharmacol Ther. 2010; 48:525–33.10.5414/CPP4852520650044SánchezJLDominguezARLaneJRAndersonPOCapparelliEVCornejo-BravoJM.Population pharmacokinetics of vancomycin in adult and geriatric patients: comparison of eleven approaches20104852533Open DOISearch in Google Scholar
Revilla N, Martin-Suárez A, Pérez MP, González FM, Fernández de Gatta Mdel M. Vancomycin dosing assessment in intensive care unit patients based on a population pharmacokinetic/pharmacodynamic simulation. Br J Clin Pharmacol. 2010; 70:201–12.10.1111/j.1365-2125.2010.03679.x20653673RevillaNMartin-SuárezAPérezMPGonzálezFMFernández de Gatta MdelM.Vancomycin dosing assessment in intensive care unit patients based on a population pharmacokinetic/pharmacodynamic simulation20107020112Open DOISearch in Google Scholar
Blouin RA, Bauer LA, Miller DD, Record KE, Griffen WO Jr. Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicrob Agents Chemother. 1982; 21:575–80.708197810.1128/AAC.21.4.575BlouinRABauerLAMillerDDRecordKEGriffenWO Jr.Vancomycin pharmacokinetics in normal and morbidly obese subjects19822157580Search in Google Scholar
Matzke GR, McGory RW, Halstenson CE, Keane WF. Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrob Agents Chemother. 1984; 25:433–7.10.1128/AAC.25.4.4336732213MatzkeGRMcGoryRWHalstensonCEKeaneWF.Pharmacokinetics of vancomycin in patients with various degrees of renal function1984254337Open DOISearch in Google Scholar
Purwonugroho TA, Chulavatnatol S, Preechagoon Y, Chindavijak B, Malathum K, Bunuparadah P. Population pharmacokinetics of vancomycin in Thai patients. ScientificWorldJournal. 2012; 2012:762649. 10.1100/2012/762649.22547995PurwonugrohoTAChulavatnatolSPreechagoonYChindavijakBMalathumKBunuparadahP.Population pharmacokinetics of vancomycin in Thai patients2012201276264910.1100/2012/762649Open DOISearch in Google Scholar
Canut A, Isla A, Betriu C, Gascón AR. Pharmacokinetic–pharmacodynamic evaluation of daptomycin, tigecycline, and linezolid versus vancomycin for the treatment of MRSA infections in four western European countries. Eur J Clin Microbiol Infect Dis. 2012; 31:2227–35.2237129410.1007/s10096-012-1560-7CanutAIslaABetriuCGascónAR.Pharmacokinetic–pharmacodynamic evaluation of daptomycin, tigecycline, and linezolid versus vancomycin for the treatment of MRSA infections in four western European countries201231222735Search in Google Scholar
Housman ST, Sutherland CA, Nicolau DP. Pharmacodynamic profile of commonly utilised parenteral therapies against meticillin-susceptible and meticillin-resistant Staphylococcus aureus collected from US hospitals. Int J Antimicrob Agents. 2014; 44:235–41.10.1016/j.ijantimicag.2014.05.01225052866HousmanSTSutherlandCANicolauDP.Pharmacodynamic profile of commonly utilised parenteral therapies against meticillin-susceptible and meticillin-resistant Staphylococcus aureus collected from US hospitals20144423541Open DOISearch in Google Scholar
Kuti JL, Kiffer CRV, Mendes CMF, Nicolau DP. Pharmacodynamic comparison of linezolid, teicoplanin and vancomycin against clinical isolates of Staphylococcus aureus and coagulase-negative staphylococci collected from hospitals in Brazil. Clin Microbiol Infect. 2008; 14:116–23.1807667210.1111/j.1469-0691.2007.01885.xKutiJLKifferCRVMendesCMFNicolauDP.Pharmacodynamic comparison of linezolid, teicoplanin and vancomycin against clinical isolates of Staphylococcus aureus and coagulase-negative staphylococci collected from hospitals in Brazil20081411623Search in Google Scholar
Mei Q, Ye Y, Zhu YL, Cheng J, Yang HF, Liu YY, et al. Use of Monte Carlo simulation to evaluate the development of vancomycin resistance in methicillin-resistant Staphylococcus aureus. Int J Antimicrob Agents. 2015; 45:652–56.10.1016/j.ijantimicag.2015.01.01825813394MeiQYeYZhuYLChengJYangHFLiuYYUse of Monte Carlo simulation to evaluate the development of vancomycin resistance in methicillin-resistant Staphylococcus aureus20154565256Open DOISearch in Google Scholar
Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet. 2004; 43:925–42.10.2165/00003088-200443130-0000515509186Moise-BroderPAForrestABirminghamMCSchentagJJ.Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections20044392542Open DOISearch in Google Scholar
Bonate PL. A brief introduction to Monte Carlo simulation. Clin Pharmacokinet. 2001; 40:15–22.1123680710.2165/00003088-200140010-00002BonatePL.A brief introduction to Monte Carlo simulation2001401522Search in Google Scholar
Roberts JA, Kirkpatrick CM, Lipman J. Monte Carlo simulations: maximizing antibiotic pharmacokinetic data to optimize clinical practice for critically ill patients. J Antimicrob Chemother. 2011; 66:227–31.10.1093/jac/dkq44921118912RobertsJAKirkpatrickCMLipmanJ.Monte Carlo simulations: maximizing antibiotic pharmacokinetic data to optimize clinical practice for critically ill patients20116622731Open DOISearch in Google Scholar
Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis. 2009; 49:507–14.1958641310.1086/600884LodiseTPPatelNLomaestroBMRodvoldKADrusanoGL.Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients20094950714Search in Google Scholar
Horey A, Mergenhagen KA, Mattappallil A. The relationship of nephrotoxicity to vancomycin trough serum concentrations in a veteran’s population: a retrospective analysis. Ann Pharmacother. 2012; 46:1477–83.10.1345/aph.1R158HoreyAMergenhagenKAMattappallilA.The relationship of nephrotoxicity to vancomycin trough serum concentrations in a veteran’s population: a retrospective analysis201246147783Open DOISearch in Google Scholar
Rybak M, Lomaestro B, Rotschafer JC, Moellering R Jr., Craig W, Billeter M, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2009; 66:82–98.10.2146/ajhp080434RybakMLomaestroBRotschaferJCMoelleringR Jr.CraigWBilleterMTherapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists2009668298Open DOISearch in Google Scholar
Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis. 2006; 42 Suppl 1:S35–9.1632311810.1086/491712RybakMJ.The pharmacokinetic and pharmacodynamic properties of vancomycin2006421S359Search in Google Scholar
Lodise TP, Graves J, Evans A, Graffunder E, Helmecke M, Lomaestro BM, et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother. 2008; 52:3315–20.10.1128/AAC.00113-0818591266LodiseTPGravesJEvansAGraffunderEHelmeckeMLomaestroBMRelationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin200852331520Open DOISearch in Google Scholar
Elyasi S, Khalili H, Dashti-Khavidaki S, Mohammadpour A. Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review. Eur J Clin Pharmacol. 2012; 68:1243–55.2241163010.1007/s00228-012-1259-9ElyasiSKhaliliHDashti-KhavidakiSMohammadpourA.Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review201268124355Search in Google Scholar
Gould IM, Cauda R, Esposito S, Gudiol F, Mazzei T, Garau J. Management of serious methicillin-resistant Staphylococcus aureus infections: what are the limits? Int J Antimicrob Agents. 2011; 37:202–9.2130052810.1016/j.ijantimicag.2010.10.030GouldIMCaudaREspositoSGudiolFMazzeiTGarauJ.Management of serious methicillin-resistant Staphylococcus aureus infections: what are the limits?2011372029Search in Google Scholar
Lodise TP, McKinnon PS, Swiderski L, Rybak MJ. Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clin Infect Dis. 2003; 36:1418–23.1276683710.1086/375057LodiseTPMcKinnonPSSwiderskiLRybakMJ.Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia200336141823Search in Google Scholar
Tsuji BT, Rybak MJ, Lau KL, Sakoulas G. Evaluation of accessory gene regulator (agr) group and function in the proclivity towards vancomycin intermediate resistance in Staphylococcus aureus. Antimicrob Agents Chemother. 2007; 51:1089–91.1715894110.1128/AAC.00671-06TsujiBTRybakMJLauKLSakoulasG.Evaluation of accessory gene regulator (agr) group and function in the proclivity towards vancomycin intermediate resistance in Staphylococcus aureus200751108991Search in Google Scholar